Biotech Values

[DewDiligence]

AGN reports mixed phase-2b NASH data:

https://finance.yahoo.com/news/data-centaur-phase-2b-clinical-120000624.html

In the patients who remained on treatment for two years, there was no significant difference between CVC and placebo in the composite endpoint – reduction in fibrosis by at least one stage with no worsening of NASH. However, in patients with higher baseline fibrosis scores, patients who received CVC had better outcomes during the two year treatment period.

CVC is the drug AGN obtained in the controversial buyout of Tobira (#msg-125266132).